Oropharyngeal Squamous Cell Carcinoma — Trials

Oropharyngeal Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 93
Recruiting: 46
Ph III recruiting: 3
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (45)

clinicaltrialsPublishedShowing 51–65 of 65 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00101348	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer	completed	Phase 1 / Phase 2	66	National Cancer Institute (NCI)NIH	1	Jun 11, 2014	clinicaltrials
NCT00049283	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer	completed	Phase 1	30	National Cancer Institute (NCI)NIH	1	Jun 6, 2014